Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.

Recombinant human growth hormone (rhGH) reduces visceral adipose tissue (VAT) volume in HIV-infected patients but can worsen glucose homeostasis and lipoatrophy. We aimed to determine if adding rosiglitazone to rhGH would abrogate the adverse effects of rhGH on insulin sensitivity (SI) and subcutane...

Full description

Bibliographic Details
Main Authors: Marshall J Glesby, Jeanine Albu, Ya-Lin Chiu, Kirsis Ham, Ellen Engelson, Qing He, Varalakshmi Muthukrishnan, Henry N Ginsberg, Daniel Donovan, Jerry Ernst, Martin Lesser, Donald P Kotler
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3625151?pdf=render

Internet

http://europepmc.org/articles/PMC3625151?pdf=render

Similar Items